Loading...
Docoh

United Therapeutics (UTHR)

United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and innovation, the power of our brands, our entrepreneurial culture and our bioinformatics leadership. We also believe that our determination to be responsible citizens - having a positive impact on patients, the environment and society - will sustain our success in the long term. Through our wholly-owned subsidiary, Lung Biotechnology PBC, we are focused on addressing the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply. Lung Biotechnology is the first public benefit corporation subsidiary of a public biotechnology or pharmaceutical company.

Company profile

Ticker
UTHR
Exchange
Website
CEO
Martine Rothblatt
Employees
Incorporated
Location
Fiscal year end
SEC CIK
Subsidiaries
Lung Bioengineering Inc. • Lung Biotechnology PBC, a Delaware public benefit corporation • Revivicor, Inc. • United Therapeutics Europe, Ltd., a company incorporated • Unither Biotech Inc. • Unither Bioelectronics, Inc. • Unither Pharma, LLC • Unither Pharmaceuticals, LLC • Unither Telmed, Ltd. • Unither Therapeutik GmbH ...
IRS number
521984749

UTHR stock data

Analyst ratings and price targets

Last 3 months

Calendar

4 May 22
17 May 22
31 Dec 22
Quarter (USD) Mar 22 Dec 21 Sep 21 Jun 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 813.3M 813.3M 813.3M 813.3M 813.3M 813.3M
Cash burn (monthly) 27.17M 1.58M (no burn) (no burn) (no burn) (no burn)
Cash used (since last report) 42.24M 2.46M n/a n/a n/a n/a
Cash remaining 771.06M 810.84M n/a n/a n/a n/a
Runway (months of cash) 28.4 512.1 n/a n/a n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
5 May 22 Dwek Raymond Common Stock Sale back to company Dispose D No Yes 186.99 2,000 373.98K 0
5 May 22 Dwek Raymond Common Stock Option exercise Acquire M No Yes 48.11 2,000 96.22K 2,000
5 May 22 Dwek Raymond Share Tracking Award Common Stock Option exercise Dispose M No Yes 48.11 2,000 96.22K 0
5 May 22 Mahon Paul A Common Stock Sell Dispose S No Yes 192.9221 700 135.05K 36,397
5 May 22 Mahon Paul A Common Stock Sell Dispose S No Yes 191.7233 900 172.55K 37,097
5 May 22 Mahon Paul A Common Stock Sell Dispose S No Yes 190.3573 3,100 590.11K 37,997
5 May 22 Mahon Paul A Common Stock Sell Dispose S No Yes 189.3765 1,300 246.19K 41,097
5 May 22 Mahon Paul A Common Stock Option exercise Acquire M No Yes 111 6,000 666K 42,397
5 May 22 Mahon Paul A Stock Options Common Stock Option exercise Dispose M No Yes 111 6,000 666K 34,552
28 Apr 22 Dwek Raymond Common Stock Sale back to company Dispose D No Yes 179.34 2,000 358.68K 0
93.8% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 405 407 -0.5%
Opened positions 54 52 +3.8%
Closed positions 56 34 +64.7%
Increased positions 134 149 -10.1%
Reduced positions 155 143 +8.4%
13F shares Current Prev Q Change
Total value 9.18B 7.96B +15.4%
Total shares 42.51M 43.09M -1.4%
Total puts 86.8K 333.51K -74.0%
Total calls 183.1K 230.18K -20.5%
Total put/call ratio 0.5 1.4 -67.3%
Largest owners Shares Value Change
BLK Blackrock 4.24M $916M -1.5%
Vanguard 4.16M $899.1M +0.0%
Avoro Capital Advisors 3.04M $655.8M +1.2%
Renaissance Technologies 2.92M $630.35M -3.7%
FMR 2.52M $545.25M +8.6%
STT State Street 1.52M $327.85M +3.7%
BK Bank Of New York Mellon 1.01M $219.1M +20.0%
Wellington Management 964.75K $208.46M +36863.4%
Geode Capital Management 760.95K $164.43M +9.0%
Fuller & Thaler Asset Management 731.39K $158.04M +4.2%
Largest transactions Shares Bought/sold Change
Wellington Management 964.75K +962.14K +36863.4%
DB Deutsche Bank AG - Registered Shares 20.52K -822.91K -97.6%
BMO Bank of Montreal 73.53K -524.09K -87.7%
Polar Capital 525.67K +432.21K +462.5%
Norges Bank 431.9K +431.9K NEW
Allspring Global Investments 358.54K +358.54K NEW
WFC Wells Fargo & Co. 81.93K -350.17K -81.0%
Acadian Asset Management 346.7K -332.4K -48.9%
Farallon Capital Management 320.76K +320.76K NEW
Pictet Asset Management 538.77K +253.35K +88.8%

Financial report summary

?
Management Discussion
  • Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
  • •The outcome of pending and potential future legal and regulatory actions by the U.S. Food and Drug Administration (FDA) and other regulatory and government enforcement agencies, and the anticipated duration of regulatory exclusivity for our products;
  • •The timing and outcome of ongoing litigation, including the lawsuit filed against us by Sandoz, Inc. (Sandoz) and Liquidia PAH, LLC (formerly known as RareGen, LLC) (RareGen); the lawsuit filed against us by MSP Recovery; our patent and trade secret litigation with Liquidia Technologies, Inc. (Liquidia) related to its NDA for Yutrepia, and with ANI Pharmaceuticals, Inc. (ANI) related to its abbreviated new drug application (ANDA) seeking FDA approval to market a generic version of Orenitram; our litigation with MSP Recovery Claims, Series LLC, and related entities; and our litigation with the U.S. Department of Health and Human Services (HHS) and the U.S. Health Resource Services Administration (HRSA) related to the Public Health Service’s 340B drug pricing program (the 340B program);

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Good
New words: Agency, aircraft, arguing, attaching, award, bioprinting, CADD, carbon, Carolina, centralized, Circuit, collateral, conflict, drone, escalation, experimental, explained, factual, feasibility, footprint, fulfill, full, gave, Heart, HSS, immunological, judge, living, magistrate, meaningful, military, moot, neighboring, nitric, North, Omicron, onset, Overnight, oxide, parent, pig, plain, plaintiff, proceed, properly, proximate, punitive, reached, repaid, rest, resumed, Robert, Roscigno, RSU, Russia, School, SOFR, stipulation, strength, suing, survived, synthase, temporary, tentative, theory, Toronto, transcend, UAB, UHeart, UKidney, Ukraine, Unitherian, Yutrepia
Removed: accessibility, accuracy, afford, amending, applied, ASP, ASU, authority, benchmark, biocompatibility, busy, cassette, chemistry, clarification, CMC, commitment, compelling, concomitant, confident, conform, considerable, consistency, consulting, contracting, cope, daily, diagnostic, distancing, donor, earliest, economy, effected, Emerging, emphysema, England, equipped, Europe, exist, expert, extremely, Facilitation, fact, FASB, feedback, fiscal, free, GAAP, hedging, identifying, immaterial, implantable, institution, issuing, Joint, lessen, LIBOR, measuring, Medtronic, municipality, optional, OreniPro, participant, pertaining, PMA, premarket, preventative, printing, prioritization, rapidly, rating, reclassified, recommended, recruit, redesign, redesigned, RemoLife, remotely, removing, repayment, responding, secondary, select, serve, Simplifying, spending, staffing, stage, standard, SteadyMed, stop, supplement, Task, Topic, training, transition, unit, utilizing, virtual, visibility, voluntary

Patents

Utility
Compounds and methods for delivery of prostacyclin analogs
5 Apr 22
This invention pertains generally to prostacyclin formulations and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis.
Utility
Genetically Modified Pigs for Xenotransplantation of Vascularized Xenografts and Derivatives Thereof
10 Mar 22
The present invention provides certain donor animals, tissues and cells that are particularly useful for xenotransplantation therapies.
Utility
Treatment of Vasculopathy with Prostacyclin and Mesenchymal Stem Cells
3 Mar 22
Provided are methods for treating or preventing vasculopathy in a subject in need thereof, comprising administering to the subject a prostacyclin and a mesenchymal stem cell (MSC) or a MSC-conditioned culture medium or administering to the subject a MSC or a MSC-conditioned culture medium that has treated with prostacyclin.
Utility
Salts of treprostinil
1 Feb 22
Provided are novel treprostinil salts as well as methods for making treprostinil salts.
Utility
Compounds and Methods for Delivery of Prostacyclin Analogs
27 Jan 22
This invention pertains generally to prostacyclin formulations and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing